Myelofibrosis Pipeline Insight

DelveInsight’s, “Myelofibrosis Pipeline Insight, 2026” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Myelofibrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Myelofibrosis Understanding

Myelofibrosis Overview

Myelofibrosis is a chronic blood cancer in which clonal abnormalities in hematopoietic stem cells drive progressive bone marrow fibrosis, resulting in ineffective blood cell production and clinical features such as anemia, splenomegaly, and fatigue. It is classified as a BCR-ABL1–negative myeloproliferative neoplasm and may arise de novo or evolve from antecedent conditions like polycythemia vera or essential thrombocythemia. The disease is strongly associated with driver mutations in JAK2, CALR, or MPL, which lead to persistent activation of the JAK-STAT signaling pathway and a pro-inflammatory cytokine milieu.

This dysregulated signaling promotes uncontrolled myeloproliferation and cytokine release, stimulating megakaryocyte expansion and fibroblast activation. As a result, excess reticulin and collagen accumulate in the marrow, progressively disrupting its architecture and function. With advancing fibrosis, hematopoiesis shifts to extramedullary sites such as the spleen and liver, leading to splenomegaly and systemic symptoms. Over time, patients develop worsening cytopenias, leukoerythroblastosis, and an increased risk of progression to acute leukemia.

Myelofibrosis diagnosis is based mainly on bone marrow morphology, with bone marrow biopsy showing megakaryocytic atypia and fibrosis, and this forms the core of the diagnostic workup. Blood tests often show abnormal counts such as anemia, leukocytosis, or leukoerythroblastosis, and a peripheral smear may suggest the disease before marrow testing. Molecular testing for JAK2, CALR, or MPL mutations supports the diagnosis, though their absence does not exclude it. Imaging such as ultrasound, CT, or MRI may be used to assess splenomegaly and organ involvement, especially when symptoms suggest advanced disease. Diagnosis also requires excluding other causes of marrow fibrosis and distinguishing primary myelofibrosis from post-ET or post-PV myelofibrosis. 

Myelofibrosis treatment is guided by symptom burden, risk category, blood counts, and eligibility for transplant, rather than a single standard approach. For many patients, JAK inhibitors such as ruxolitinib are the main drug therapy because they reduce spleen size and improve constitutional symptoms. Other approved JAK inhibitors, including fedratinib, pacritinib, and momelotinib, are used in selected patients depending on risk status and issues such as anemia or thrombocytopenia. Supportive care may include blood transfusions, medications for anemia, and sometimes splenectomy or radiation for difficult spleen-related symptoms. The only potentially curative option is allogeneic stem cell transplant, but it is reserved for carefully selected higher-risk patients because of its significant toxicity.

"Myelofibrosis Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Myelofibrosis pipeline landscape is provided which includes the disease overview and Myelofibrosis treatment guidelines. The assessment part of the report embraces, in depth Myelofibrosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Myelofibrosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Discover the latest Myelofibrosis pipeline insights, emerging therapies, and clinical advancements shaping the future of treatment in 2026.

Myelofibrosis Pipeline Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Myelofibrosis R&D. The therapies under development are focused on novel approaches to treat/improve Myelofibrosis.

Myelofibrosis Emerging Drugs Analysis

This segment of the Myelofibrosis report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Myelofibrosis Emerging Drugs

Ropeginterferon alfa-2b: PharmaEssentia Corporation

Ropeginterferon alfa-2b is a long-acting, mono-pegylated interferon designed for sustained activation of interferon signaling with improved tolerability and convenient dosing compared to earlier interferons. It exerts antiproliferative and immunomodulatory effects, helping to suppress malignant hematopoietic clones and restore more normal bone marrow function. The drug is currently being studied in a Phase III clinical trial for the treatment of Myelofibrosis.

Roginolisib: iOnctura

Roginolisib is an orally available, first-in-class allosteric modulator of PI3Kδ, distinguished by its unique binding mode that alters the protein’s 3D conformation and selectively inhibits its activity. By targeting the PI3Kδ isoform commonly dysregulated in cancers and expressed in immunosuppressive cells, it aims to reverse tumor-associated immune suppression while directly inhibing malignant cell proliferation. In myelofibrosis, Roginolisib may help counteract immune-mediated resistance mechanisms that limit current therapies. It is currently being evaluated in a Phase II clinical trial for the treatment of Myelofibrosis.

RVU120: Ryvu Therapeutics

RVU120 is an oral, selective inhibitor of CDK8 and CDK19, key regulators of transcriptional pathways involved in oncogenesis and inflammation. In Myelofibrosis, it modulates aberrant signaling such as STAT-driven pathways, helping to suppress malignant hematopoietic cell proliferation. The drug has demonstrated potential disease-modifying activity, including reduction of inflammatory cytokines and fibrosis-associated signaling. RVU120 is currently in Phase II of its clinical development, with early studies indicating activity in patients resistant or refractory to JAK inhibitor therapies.

PRT12396: Prelude Therapeutics

PRT12396 is a mutant-selective JAK2V617F inhibitor being developed for the treatment of patients with certain myeloproliferative neoplasms (MPNs). It has received Investigational New Drug (IND) clearance from the US Food and Drug Administration, enabling clinical evaluation in advanced malignancies, including hematologic cancers. It is currently being evaluated in a Phase I clinical trial for the treatment of Myelofibrosis.

Further product details are provided in the report……..

Myelofibrosis Drug Therapeutic Assessment

This segment of the report provides insights about the different Myelofibrosis drugs segregated based on following parameters that define the scope of the report, such as:

Major Myelofibrosis Players in Myelofibrosis

There are approx. 50+ key companies which are developing the therapies for Myelofibrosis. The companies which have their Myelofibrosis drug candidates in the most advanced stage, i.e. Phase III include, PharmaEssentia Corporation.

Myelofibrosis Clinical Trial Phases

DelveInsight’s report covers around 55+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Myelofibrosis Drug Route of Administration

Myelofibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral 
• Topical

Myelofibrosis Product Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer 
• Gene therapy

Myelofibrosis Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Myelofibrosis Clinical Trial Activities

The Myelofibrosis Pipeline report provides insights into different Myelofibrosis Clinical Trials within Phase III, II, I, preclinical and discovery stage. It also analyses Myelofibrosis therapeutic drugs key players involved in developing key drugs. 

Myelofibrosis Pipeline Development Activities

The Myelofibrosis Clinical Trial Analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Myelofibrosis drugs.

Myelofibrosis Pipeline Report Insights

• Myelofibrosis Pipeline Analysis
• Myelofibrosis Therapeutic Assessment
• Myelofibrosis Unmet Needs
• Impact of Myelofibrosis Drugs

Myelofibrosis Pipeline Report Assessment

• Myelofibrosis Pipeline Product Profiles
• Myelofibrosis Therapeutic Assessment
• MyelofibrosisPipeline Assessment
• Myelofibrosis Inactive drugs assessment
• Myelofibrosis Market Unmet Needs

Discover actionable insights into the Myelofibrosis market trends, epidemiology trends, and forecast through 2036 to stay ahead in emerging therapies.

Key Questions Answered In The Myelofibrosis Pipeline Report:

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Myelofibrosis drugs?
• How many Myelofibrosis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Myelofibrosis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Myelofibrosis therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for Myelofibrosis and their status?
• What are the key designations that have been granted to the emerging drugs?

Myelofibrosis Key Companies

• PharmaEssentia Corporation
• iOnctura
• Prelude Therapeutics
• Cellenkos
• Ajax Therapeutics
• Eilean Therapeutics
• Phoenix Molecular Designs
• Ryvu Therapeutics
• Disc Medicine
• Sumitomo Pharmas
• CERo Therapeutics
• Stemline Therapeutics
• Incyte Corporation
• Takeda
• Syntara Limited
• Opna Bio
• Epigenetix
• Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• GluBio Therapeutics
• Telios Pharma, Inc.
• Sumitomo Pharma

Myelofibrosis Key Products

• Ropeginterferon alfa-2b
• Roginolisib
• PRT12396
• CK0804
• AJ1-11095
• ZE74-0282
• PMD-026
• RVU120
• DISC-0974
• Nuvisertib
• CER 1236
• Tagraxofusp
• INCA035784
• Elritercept
• Amsulostat
• Zavabresib
• EP-31670
• TQB3617
• GLB-001
• TL-895
• Nuvisertib

Explore comprehensive insights into Myelofibrosis epidemiology trends, patient population forecasts, and growth opportunities through 2034 for strategic decision-making.